Zacks Investment Research upgraded shares of Oncobiologics Inc (NYSE:ONS) from a hold rating to a buy rating in a research report sent to investors on Saturday, June 10th. Zacks Investment Research currently has $1.75 price objective on the stock.
According to Zacks, “Oncobiologics, Inc. is a clinical-stage biopharmaceutical company which engaged in identifying, developing, manufacturing and commercializing complex biosimilar therapeutics in the disease areas of immunology and oncology. Its product pipeline consists of ONS-3010, ONS-1045, ONS-1050, ONS-1055, ONS-4010, ONS-3030, ONS-3035 and ONS-3040 which are in preclinical stage. The company employs its BioSymphony(TM) Platform to address the challenges of biosimilar development and commercialization by developing mAb biosimilars. Oncobiologics, Inc. is headquartered in Cranbury, New Jersey. “
Other research analysts have also issued reports about the company. Cantor Fitzgerald reissued a buy rating and issued a $15.00 price objective on shares of Oncobiologics in a report on Thursday, April 13th. Jefferies Group LLC reissued a hold rating and issued a $3.00 price objective on shares of Oncobiologics in a report on Wednesday, April 12th.
Oncobiologics (ONS) opened at 1.41 on Friday. The firm has a 50-day moving average price of $1.69 and a 200 day moving average price of $2.56. Oncobiologics has a 12 month low of $1.13 and a 12 month high of $5.49. The stock’s market capitalization is $34.48 million.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.